Phaseline

Targets › IL2R

IL2R: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Nov 2027.

Open in Phaseline: the race on IL2R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The First Affiliated Hospital of Xiamen UniversityRecombinant Human Interleukin-2 Injections
IL-2 receptor agonist
IL2RPhase 2Hematological MalignancyNov 2027

Conditions

Hematological Malignancy (1)

Modalities

protein or peptide (1)

Companies

The First Affiliated Hospital of Xiamen University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.